儿童初级保健中下呼吸道感染的抗生素治疗(ARTIC-PC):分子检测的预测价值
该研究评估儿童初级保健中无并发症下呼吸道感染(LRTI)时上呼吸道细菌或病毒存在是否预测抗生素获益。6个月至12岁患儿随机接受阿莫西林50 mg/kg/d 7天或安慰剂,主要结局为症状评为中度差或更差的持续时间。结果发现无论潜在抗生素敏感细菌存在与否,抗生素与安慰剂间症状持续时间差异相似。
要点
- 上呼吸道潜在抗生素敏感细菌存在与否,抗生素与安慰剂症状持续时间差异相似。
- 细菌基因组拷贝数未预测抗生素获益。
- 所有次要结局及纳入观察性研究数据后结果相似。
核心结论
- 无明确证据表明抗生素改善临床结局取决于上呼吸道细菌或病毒的存在或浓度。
研究设计与样本
- 在UK全科诊所就诊的6个月至12岁急性LRTI儿童随机接受阿莫西林50 mg/kg/d 7天或安慰剂,未随机儿童可参与平行观察性研究。
主要发现
- 试验中306/432(71%)和观察性研究中182/326(59%)参与者有拭子结果。
- 试验安慰剂组51%和试验抗生素组49%检测到潜在阿莫西林敏感细菌(流感嗜血杆菌、卡他莫拉菌、肺炎链球菌)。
- 潜在抗生素敏感细菌存在时,抗生素与安慰剂间症状评为中度差或更差的持续时间中位差异为-1天(99% CI,-12.3至10.3);不存在时为-1天(99% CI,-4.5至2.5)。
- 细菌基因组拷贝数未预测获益。
- 所有次要结局及纳入观察性研究数据后结果相似。
临床怎么用
- 在初级保健中为无并发症LRTI儿童部署微生物学即时检测前,需进行严格验证试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to assess whether the presence of bacteria or viruses in the upper airway of children presenting with uncomplicated lower respiratory tract infection (LRTI) predicts the benefit of antibiotics. METHODS: Children between 6 months and 12 years presenting to UK general practices with an acute LRTI were randomized to receive amoxicillin 50 mg/kg/d for 7 days or placebo. Children not randomized (ineligible or clinician/parental choice) could participate in a parallel observational study. The primary outcome was the duration of symptoms rated moderately bad or worse. Throat swabs were taken and analyzed for the presence of bacteria and viruses by multiplex PCR. RESULTS: Swab results were available for most participants in the trial (306 of 432; 71%) and in the observational (182 of 326; 59%) studies. Bacterial pathogens potentially sensitive to amoxicillin (Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae) were detected among 51% of the trial placebo group and 49% of the trial antibiotic group. The median difference in the duration of symptoms rated moderately bad or worse between antibiotic and placebo was similar when potentially antibiotic-susceptible bacteria were present (median: -1 day; 99% CI, -12.3 to 10.3) or not present (median: -1 day; 99% CI, -4.5 to 2.5). Furthermore, bacterial genome copy number did not predict benefit. There were similar findings for all secondary outcomes and when including the data from the observational study. DISCUSSION: There was no clear evidence that antibiotics improved clinical outcomes conditional on the presence or concentration of bacteria or viruses in the upper airway. Before deploying microbiologic point-of-care tests for children with uncomplicated LRTI in primary care, rigorous validating trials are needed.
引用
- Little P, Read RC, Becque T, et al. Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC-PC): the predictive value of molecular testing. Clin Microbiol Infect. 2022. PMID: 35289295. doi:10.1016/j.cmi.2022.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。